{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:26:42Z","timestamp":1788276402256,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-026-01836-0","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:26:05Z","timestamp":1785410765000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A modular \u03b3\u03b4 TCR-T platform combining KRAS pMHC targeting with re-dosable mRNA engager redirection"],"prefix":"10.1186","volume":"19","author":[{"given":"\u00c1ngel","family":"Ram\u00edrez-Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adham S.","family":"Bear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elahe","family":"Kamali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bartoszek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin","family":"Dersh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"C\u00f3rdoba-Espejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiageng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mosha","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Velasco-Sidro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankita","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Han","family":"Noll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin R","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen","family":"Koucky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janna","family":"Minehart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J.","family":"Dimitri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Lavorando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Segura-Tudela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Scholler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Barber-Rotenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie K.","family":"Jadlowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa E.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald L.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce L.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Lotze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl H.","family":"June","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Vonderheide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Fraietta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"1836_CR1","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377:2531\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1707447.","journal-title":"N Engl J Med"},{"key":"1836_CR2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378:439\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1709866.","journal-title":"N Engl J Med"},{"key":"1836_CR3","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan RA, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18:843\u201351. https:\/\/doi.org\/10.1038\/mt.2010.24.","journal-title":"Mol Ther"},{"key":"1836_CR4","doi-asserted-by":"publisher","first-page":"100089","DOI":"10.1016\/j.iotech.2022.100089","volume":"15","author":"MW Rohaan","year":"2022","unstructured":"Rohaan MW, et al. MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I\/IIa clinical trial. Immunooncol Technol. 2022;15:100089. https:\/\/doi.org\/10.1016\/j.iotech.2022.100089.","journal-title":"Immunooncol Technol"},{"key":"1836_CR5","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","volume":"122","author":"GP Linette","year":"2013","unstructured":"Linette GP, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013;122:863\u201371. https:\/\/doi.org\/10.1182\/blood-2013-03-490565.","journal-title":"Blood"},{"key":"1836_CR6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","volume":"36","author":"RA Morgan","year":"2013","unstructured":"Morgan RA, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 2013;36:133\u201351. https:\/\/doi.org\/10.1097\/CJI.0b013e3182829903.","journal-title":"J Immunother"},{"key":"1836_CR7","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","volume":"114","author":"LA Johnson","year":"2009","unstructured":"Johnson LA, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009;114:535\u201346. https:\/\/doi.org\/10.1182\/blood-2009-03-211714.","journal-title":"Blood"},{"key":"1836_CR8","doi-asserted-by":"publisher","unstructured":"O\u2019Rourke DM, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9. https:\/\/doi.org\/10.1126\/scitranslmed.aaa0984.","DOI":"10.1126\/scitranslmed.aaa0984"},{"key":"1836_CR9","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","volume":"29","author":"PF Robbins","year":"2011","unstructured":"Robbins PF, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29:917\u201324. https:\/\/doi.org\/10.1200\/JCO.2010.32.2537.","journal-title":"J Clin Oncol"},{"key":"1836_CR10","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","volume":"80","author":"IA Prior","year":"2020","unstructured":"Prior IA, Hood FE, Hartley JL. The Frequency of Ras Mutations in Cancer. Cancer Res. 2020;80:2969\u201374. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-3682.","journal-title":"Cancer Res"},{"key":"1836_CR11","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1126\/science.aec7929","volume":"391","author":"MT Than","year":"2026","unstructured":"Than MT, et al. Cancer interception with KRAS inhibitors in preclinical models of pancreatic ductal adenocarcinoma. Science. 2026;391:1161\u20136. https:\/\/doi.org\/10.1126\/science.aec7929.","journal-title":"Science"},{"key":"1836_CR12","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","volume":"375","author":"E Tran","year":"2016","unstructured":"Tran E, et al. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N Engl J Med. 2016;375:2255\u201362. https:\/\/doi.org\/10.1056\/NEJMoa1609279.","journal-title":"N Engl J Med"},{"key":"1836_CR13","doi-asserted-by":"publisher","first-page":"6389","DOI":"10.1038\/s41467-023-42010-1","volume":"14","author":"D Lu","year":"2023","unstructured":"Lu D, et al. KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors. Nat Commun. 2023;14:6389. https:\/\/doi.org\/10.1038\/s41467-023-42010-1.","journal-title":"Nat Commun"},{"key":"1836_CR14","doi-asserted-by":"publisher","unstructured":"Bear AS, et al. Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumors. J Clin Invest. 2024;134. https:\/\/doi.org\/10.1172\/JCI175790.","DOI":"10.1172\/JCI175790"},{"key":"1836_CR15","doi-asserted-by":"publisher","unstructured":"Xu X, et al. Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients. JCI Insight. 2025;10. https:\/\/doi.org\/10.1172\/jci.insight.181873.","DOI":"10.1172\/jci.insight.181873"},{"key":"1836_CR16","doi-asserted-by":"publisher","unstructured":"Shen M, et al. Therapeutic potential of T-cell receptor targeting the HLA-A*11:01-restricted KRAS(G12V) neoantigen without cross-recognition of the self-antigen RAB7B in solid tumors. J Immunother Cancer. 2025;13. https:\/\/doi.org\/10.1136\/jitc-2025-011863.","DOI":"10.1136\/jitc-2025-011863"},{"key":"1836_CR17","doi-asserted-by":"publisher","unstructured":"McGranahan N et al. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell 171, 1259\u20131271 e1211 (2017). https:\/\/doi.org\/10.1016\/j.cell.2017.10.001","DOI":"10.1016\/j.cell.2017.10.001"},{"key":"1836_CR18","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med. 2016;375:819\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1604958.","journal-title":"N Engl J Med"},{"key":"1836_CR19","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1007\/s11033-010-0053-y","volume":"37","author":"H Shao","year":"2010","unstructured":"Shao H, et al. TCR mispairing in genetically modified T cells was detected by fluorescence resonance energy transfer. Mol Biol Rep. 2010;37:3951\u20136. https:\/\/doi.org\/10.1007\/s11033-010-0053-y.","journal-title":"Mol Biol Rep"},{"key":"1836_CR20","doi-asserted-by":"publisher","unstructured":"Bendle GM et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med 16, 565\u2013570, 561p following 570 (2010). https:\/\/doi.org\/10.1038\/nm.2128","DOI":"10.1038\/nm.2128"},{"key":"1836_CR21","doi-asserted-by":"publisher","unstructured":"Bethune MT, et al. Domain-swapped T cell receptors improve the safety of TCR gene therapy. Elife. 2016;5. https:\/\/doi.org\/10.7554\/eLife.19095.","DOI":"10.7554\/eLife.19095"},{"key":"1836_CR22","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/s41551-019-0409-0","volume":"3","author":"K Schober","year":"2019","unstructured":"Schober K, et al. Orthotopic replacement of T-cell receptor alpha- and beta-chains with preservation of near-physiological T-cell function. Nat Biomed Eng. 2019;3:974\u201384. https:\/\/doi.org\/10.1038\/s41551-019-0409-0.","journal-title":"Nat Biomed Eng"},{"key":"1836_CR23","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41586-018-0326-5","volume":"559","author":"TL Roth","year":"2018","unstructured":"Roth TL, et al. Reprogramming human T cell function and specificity with non-viral genome targeting. Nature. 2018;559:405\u20139. https:\/\/doi.org\/10.1038\/s41586-018-0326-5.","journal-title":"Nature"},{"key":"1836_CR24","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41586-022-05531-1","volume":"615","author":"SP Foy","year":"2023","unstructured":"Foy SP, et al. Non-viral precision T cell receptor replacement for personalized cell therapy. Nature. 2023;615:687\u201396. https:\/\/doi.org\/10.1038\/s41586-022-05531-1.","journal-title":"Nature"},{"key":"1836_CR25","doi-asserted-by":"publisher","unstructured":"Rigau M, et al. Butyrophilin 2A1 is essential for phosphoantigen reactivity by gammadelta T cells. Science. 2020;367. https:\/\/doi.org\/10.1126\/science.aay5516.","DOI":"10.1126\/science.aay5516"},{"key":"1836_CR26","doi-asserted-by":"publisher","unstructured":"Karunakaran MM et al. Butyrophilin-2A1 Directly Binds Germline-Encoded Regions of the Vgamma9Vdelta2 TCR and Is Essential for Phosphoantigen Sensing. Immunity 52, 487\u2013498 e486 (2020). https:\/\/doi.org\/10.1016\/j.immuni.2020.02.014","DOI":"10.1016\/j.immuni.2020.02.014"},{"key":"1836_CR27","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/s41586-023-06525-3","volume":"621","author":"L Yuan","year":"2023","unstructured":"Yuan L, et al. Phosphoantigens glue butyrophilin 3A1 and 2A1 to activate Vgamma9Vdelta2 T cells. Nature. 2023;621:840\u20138. https:\/\/doi.org\/10.1038\/s41586-023-06525-3.","journal-title":"Nature"},{"key":"1836_CR28","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.3909","volume":"21","author":"AJ Gentles","year":"2015","unstructured":"Gentles AJ, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21:938\u201345. https:\/\/doi.org\/10.1038\/nm.3909.","journal-title":"Nat Med"},{"key":"1836_CR29","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41423-020-0515-7","volume":"18","author":"Y Xu","year":"2021","unstructured":"Xu Y, et al. Allogeneic Vgamma9Vdelta2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer. Cell Mol Immunol. 2021;18:427\u201339. https:\/\/doi.org\/10.1038\/s41423-020-0515-7.","journal-title":"Cell Mol Immunol"},{"key":"1836_CR30","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/(SICI)1097-0320(19991215)38:6<280::AID-CYTO4>3.0.CO;2-G","volume":"38","author":"J McClanahan","year":"1999","unstructured":"McClanahan J, Fukushima PI, Stetler-Stevenson M. Increased peripheral blood gamma delta T-cells in patients with lymphoid neoplasia: A diagnostic dilemma in flow cytometry. Cytometry. 1999;38:280\u20135.","journal-title":"Cytometry"},{"key":"1836_CR31","doi-asserted-by":"publisher","first-page":"e1373","DOI":"10.1002\/cti2.1373","volume":"11","author":"KP Nishimoto","year":"2022","unstructured":"Nishimoto KP, et al. Allogeneic CD20-targeted gammadelta T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma models. Clin Transl Immunol. 2022;11:e1373. https:\/\/doi.org\/10.1002\/cti2.1373.","journal-title":"Clin Transl Immunol"},{"key":"1836_CR32","doi-asserted-by":"publisher","first-page":"164","DOI":"10.4049\/jimmunol.182.1.164","volume":"182","author":"LT van der Veken","year":"2009","unstructured":"van der Veken LT, et al. Alpha beta T cell receptor transfer to gamma delta T cells generates functional effector cells without mixed TCR dimers in vivo. J Immunol. 2009;182:164\u201370. https:\/\/doi.org\/10.4049\/jimmunol.182.1.164.","journal-title":"J Immunol"},{"key":"1836_CR33","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1158\/0008-5472.CAN-05-4190","volume":"66","author":"LT van der Veken","year":"2006","unstructured":"van der Veken LT, et al. Alphabeta T-cell receptor engineered gammadelta T cells mediate effective antileukemic reactivity. Cancer Res. 2006;66:3331\u20137. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-4190.","journal-title":"Cancer Res"},{"key":"1836_CR34","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/gt.2009.6","volume":"16","author":"A Hiasa","year":"2009","unstructured":"Hiasa A, et al. Rapid alphabeta TCR-mediated responses in gammadelta T cells transduced with cancer-specific TCR genes. Gene Ther. 2009;16:620\u20138. https:\/\/doi.org\/10.1038\/gt.2009.6.","journal-title":"Gene Ther"},{"key":"1836_CR35","doi-asserted-by":"publisher","first-page":"e2205532","DOI":"10.1002\/advs.202205532","volume":"10","author":"C Huang","year":"2023","unstructured":"Huang C, et al. Lipid Nanoparticle Delivery System for mRNA Encoding B7H3-redirected Bispecific Antibody Displays Potent Antitumor Effects on Malignant Tumors. Adv Sci (Weinh). 2023;10:e2205532. https:\/\/doi.org\/10.1002\/advs.202205532.","journal-title":"Adv Sci (Weinh)"},{"key":"1836_CR36","doi-asserted-by":"publisher","unstructured":"Golubovskaya V, et al. mRNA-Lipid Nanoparticle (LNP) Delivery of Humanized EpCAM-CD3 Bispecific Antibody Significantly Blocks Colorectal Cancer Tumor Growth. Cancers (Basel). 2023;15. https:\/\/doi.org\/10.3390\/cancers15102860.","DOI":"10.3390\/cancers15102860"},{"key":"1836_CR37","doi-asserted-by":"publisher","first-page":"11111","DOI":"10.1038\/s41467-025-66087-y","volume":"16","author":"Y Huang","year":"2025","unstructured":"Huang Y, et al. Organ-specific delivery of an mRNA-encoded bispecific T cell engager targeting glypican-3 in hepatocellular carcinoma. Nat Commun. 2025;16:11111. https:\/\/doi.org\/10.1038\/s41467-025-66087-y.","journal-title":"Nat Commun"},{"key":"1836_CR38","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","volume":"2","author":"GL Beatty","year":"2014","unstructured":"Beatty GL, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014;2:112\u201320. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0170.","journal-title":"Cancer Immunol Res"},{"key":"1836_CR39","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","volume":"155","author":"GL Beatty","year":"2018","unstructured":"Beatty GL, et al. Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. Gastroenterology. 2018;155:29\u201332. https:\/\/doi.org\/10.1053\/j.gastro.2018.03.029.","journal-title":"Gastroenterology"},{"key":"1836_CR40","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1038\/s41467-021-24562-2","volume":"12","author":"AS Bear","year":"2021","unstructured":"Bear AS, et al. Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting. Nat Commun. 2021;12:4365. https:\/\/doi.org\/10.1038\/s41467-021-24562-2.","journal-title":"Nat Commun"},{"key":"1836_CR41","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/mt.sj.6300134","volume":"15","author":"MM Suhoski","year":"2007","unstructured":"Suhoski MM, et al. Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol Ther. 2007;15:981\u20138. https:\/\/doi.org\/10.1038\/mt.sj.6300134.","journal-title":"Mol Ther"},{"key":"1836_CR42","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","volume":"26","author":"CC Kloss","year":"2018","unstructured":"Kloss CC, et al. Dominant-Negative TGF-beta Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. Mol Ther. 2018;26:1855\u201366. https:\/\/doi.org\/10.1016\/j.ymthe.2018.05.003.","journal-title":"Mol Ther"},{"key":"1836_CR43","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1056\/NEJMoa1300662","volume":"370","author":"P Tebas","year":"2014","unstructured":"Tebas P, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 2014;370:901\u201310. https:\/\/doi.org\/10.1056\/NEJMoa1300662.","journal-title":"N Engl J Med"},{"key":"1836_CR44","doi-asserted-by":"publisher","first-page":"307ra156","DOI":"10.1126\/scitranslmed.aac5530","volume":"7","author":"BD Sather","year":"2015","unstructured":"Sather BD, et al. Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci Transl Med. 2015;7:307ra156. https:\/\/doi.org\/10.1126\/scitranslmed.aac5530.","journal-title":"Sci Transl Med"},{"key":"1836_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-025-01527-0","author":"A Ramirez-Fernandez","year":"2025","unstructured":"Ramirez-Fernandez A, et al. CCR5-targeted allogeneic gamma-delta CD19 chimeric antigen receptor T cells for HIV-associated B cell-malignancy immunotherapy. Nat Biomed Eng. 2025. https:\/\/doi.org\/10.1038\/s41551-025-01527-0.","journal-title":"Nat Biomed Eng"},{"key":"1836_CR46","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/mt.2010.85","volume":"18","author":"A Akinc","year":"2010","unstructured":"Akinc A, et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther. 2010;18:1357\u201364. https:\/\/doi.org\/10.1038\/mt.2010.85.","journal-title":"Mol Ther"},{"key":"1836_CR47","doi-asserted-by":"publisher","first-page":"6709","DOI":"10.1021\/acsnano.0c10064","volume":"15","author":"F Sebastiani","year":"2021","unstructured":"Sebastiani F, et al. Apolipoprotein E Binding Drives Structural and Compositional Rearrangement of mRNA-Containing Lipid Nanoparticles. ACS Nano. 2021;15:6709\u201322. https:\/\/doi.org\/10.1021\/acsnano.0c10064.","journal-title":"ACS Nano"},{"key":"1836_CR48","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ymthe.2019.10.001","volume":"28","author":"LT Morton","year":"2020","unstructured":"Morton LT, et al. Simultaneous Deletion of Endogenous TCRalphabeta for TCR Gene Therapy Creates an Improved and Safe Cellular Therapeutic. Mol Ther. 2020;28:64\u201374. https:\/\/doi.org\/10.1016\/j.ymthe.2019.10.001.","journal-title":"Mol Ther"},{"key":"1836_CR49","doi-asserted-by":"publisher","first-page":"5708","DOI":"10.1158\/1078-0432.CCR-13-3451","volume":"20","author":"DC Deniger","year":"2014","unstructured":"Deniger DC, et al. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies. Clin Cancer Res. 2014;20:5708\u201319. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-3451.","journal-title":"Clin Cancer Res"},{"key":"1836_CR50","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.jcyt.2017.12.014","volume":"20","author":"L Xiao","year":"2018","unstructured":"Xiao L, et al. Large-scale expansion of Vgamma9Vdelta2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor-modified effector cells. Cytotherapy. 2018;20:420\u201335. https:\/\/doi.org\/10.1016\/j.jcyt.2017.12.014.","journal-title":"Cytotherapy"},{"key":"1836_CR51","doi-asserted-by":"publisher","unstructured":"Bak RO et al. Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR\/Cas9 and AAV6. Elife 6 (2017). https:\/\/doi.org\/10.7554\/eLife.27873","DOI":"10.7554\/eLife.27873"},{"key":"1836_CR52","doi-asserted-by":"publisher","first-page":"615317","DOI":"10.3389\/fimmu.2020.615317","volume":"11","author":"CG Graydon","year":"2020","unstructured":"Graydon CG, Mohideen S, Fowke KR. LAG3\u2019s Enigmatic Mechanism of Action. Front Immunol. 2020;11:615317. https:\/\/doi.org\/10.3389\/fimmu.2020.615317.","journal-title":"Front Immunol"},{"key":"1836_CR53","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/nm.4356","volume":"23","author":"CR Stadler","year":"2017","unstructured":"Stadler CR, et al. Elimination of large tumors in mice by mRNA-encoded bispecific antibodies. Nat Med. 2017;23:815\u20137. https:\/\/doi.org\/10.1038\/nm.4356.","journal-title":"Nat Med"},{"key":"1836_CR54","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41551-026-01633-7","volume":"10","author":"GM Chen","year":"2026","unstructured":"Chen GM, et al. Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer. Nat Biomed Eng. 2026;10:803\u201314. https:\/\/doi.org\/10.1038\/s41551-026-01633-7.","journal-title":"Nat Biomed Eng"},{"key":"1836_CR55","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","volume":"27","author":"AR Haas","year":"2019","unstructured":"Haas AR, et al. Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. Mol Ther. 2019;27:1919\u201329. https:\/\/doi.org\/10.1016\/j.ymthe.2019.07.015.","journal-title":"Mol Ther"},{"key":"1836_CR56","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","volume":"21","author":"SM Albelda","year":"2024","unstructured":"Albelda SM. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat Rev Clin Oncol. 2024;21:47\u201366. https:\/\/doi.org\/10.1038\/s41571-023-00832-4.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01836-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01836-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01836-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:07:28Z","timestamp":1788275248000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01836-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1836"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01836-0","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"27 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"B.L.L.: Consultancy and advisory roles with Terumo, GSK, and Kite; co-founder and equity holder in Tmunity Therapeutics (acquired by Kite) and Capstan Therapeutics; advisory board memberships with Avectas, Capstan (Chair), Immuneel, Immusoft, In8bio, Ori Biotech, Oxford Biomedica, ThermoFisher Pharma Services, and UTC Therapeutics; member of the Alliance for Cancer Gene Therapy Board of Directors. C.H.J.: Receives royalties from Novartis and Kite paid to the University of Pennsylvania; scientific co-founder and equity holder in Capstan Therapeutics, Dispatch Biotherapeutics, and Bluewhale Bio; board member of AC Immune; scientific advisory roles with various companies, including BluesphereBio, Cabaletta, Carisma, Cartography, Cellares, Cellcarta, Celldex, Danaher, Decheng, ImmuneSensor, Kite, Poseida, Verismo, Viracta, and WIRB-Copernicus group. JLR received sponsored research to support these studies from Tmunity\/Kite Pharma. JLR is a scientific founder of Tmunity Therapeutics which was acquired by Kite Pharma and he recently served as a paid Scientific Advisor. He also is a scientific founder BlueWhale Bio where he serves as an unpaid Scientific Advisor. He had (Tmunity) or has (BlueWhale) an equity interest in these companies. J.A.F.: Holds patents and intellectual property in T-cell-based cancer immunotherapy with royalties; receives funding from Tmunity Therapeutics and Danaher Corporation; consultancy with Retro Biosciences; scientific advisory board memberships with Cartography Bio, Shennon Biotechnologies Inc., CellFe Biotech, OverT Bio, Inc., and Tceleron Therapeutics, Inc. All other authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"72"}}